Inclusion Criteria:  Have provided written and signed informed consent; Histologically confirmed invasive ductal carcinoma; Planned to received (neo)/adjuvant chemotherapy; Eastern Cooperative Oncology Group (ECOG) score of 0 to 1; Normal blood routine, liver and kidney functions within 1 week before enrollment in this study; Women of childbearing age have a negative serum or urinary pregnancy tests prior to enrollment in this study; Pre-menopause women are contracepted with medically acceptable methods during the study period. Compliance with the study protocol.  Exclusion Criteria:  Pregnant or breast feeding; Eastern Cooperative Oncology Group (ECOG) score ≥ 2; Hypersensitivity to moxifloxacin or quinolones compounds; Concomitant with other antitumor therapies or participating in other clinical trials; Have a history of heart disease, such as arrhythmia, conduction block, S-T segment elevation, ischemic heart disease, or congenital heart disease; Severe uncontrolled co-infection, or severe metabolic disorders; A clear past history of neurological or psychiatric disorders, including epilepsy or dementia; Poor compliance, unwillingness or inability to follow protocol to continue the study; Any circumstances in which the investigator deemed the subject unsuitable for enrollment in this study.